ERBB2 and breast cancer: In patients with newly diagnosed brain metastasis, this clinical trial suggested that early clearance of CTCs detected by CellSearch in patients' blood was correlated with brain metastasis response to a targeted therapy in HER2‐positive breast cancers.66